Regional News • World

AstraZeneca's vaccine has limited efficacy against South Africa variant – research

AstraZeneca's Covid-19 vaccine offers limited protection against mild infection of the South African variant (B.1.351). This is according to initial results of a study conducted by South Africa's University of Witwatersrand and Oxford University, with which AstraZeneca co-developed the vaccine. Oxford University and AstraZeneca are reportedly adapting the vaccine for the mutation and predict it will be ready by autumn.

Highly edible human, designer of all things digital, co-founder of Pendect, creative native, constant wa/onderer, morse code lady, full-time dog pillow.
Card reviewed by: @christoph